192 related articles for article (PubMed ID: 26302462)
1. Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy in a real-life scenario.
Campennì A; Giovanella L; Pignata SA; Violi MA; Siracusa M; Alibrandi A; Moleti M; Amato E; Ruggeri RM; Vermiglio F; Baldari S
Nucl Med Commun; 2015 Nov; 36(11):1100-6. PubMed ID: 26302462
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose.
Campennì A; Amato E; Laudicella R; Alibrandi A; Cardile D; Pignata SA; Trimarchi F; Ruggeri RM; Auditore L; Baldari S
Endocrine; 2019 Jul; 65(1):132-137. PubMed ID: 30875058
[TBL] [Abstract][Full Text] [Related]
3. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma.
Luster M; Sherman SI; Skarulis MC; Reynolds JR; Lassmann M; Hänscheid H; Reiners C
Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1371-7. PubMed ID: 12856155
[TBL] [Abstract][Full Text] [Related]
4. Thyroid remnant ablation success and disease outcome in stage III or IV differentiated thyroid carcinoma: recombinant human thyrotropin versus thyroid hormone withdrawal.
Vallejo Casas JA; Mena Bares LM; Gálvez Moreno MA; Moreno Ortega E; Marlowe RJ; Maza Muret FR; Albalá González MD
Q J Nucl Med Mol Imaging; 2016 Jun; 60(2):163-71. PubMed ID: 26563902
[TBL] [Abstract][Full Text] [Related]
5. Thyroid Uptake and Effective Half-Life of Radioiodine in Thyroid Cancer Patients at Radioiodine Therapy and Follow-Up Whole-Body Scintigraphy Either in Hypothyroidism or Under rhTSH.
Bacher R; Hohberg M; Dietlein M; Wild M; Kobe C; Drzezga A; Schmidt M
J Nucl Med; 2019 May; 60(5):631-637. PubMed ID: 30315143
[TBL] [Abstract][Full Text] [Related]
6. rhTSH-aided low-activity versus high-activity regimens of radioiodine in residual ablation for differentiated thyroid cancer: a meta-analysis.
Ma C; Tang L; Fu H; Li J; Wang H
Nucl Med Commun; 2013 Dec; 34(12):1150-6. PubMed ID: 24025918
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human thyroid-stimulating hormone in radioiodine thyroid remnant ablation.
Mylonas C; Zwas ST; Rotenberg G; Omry G; Cohen O
Isr Med Assoc J; 2014 Feb; 16(2):106-9. PubMed ID: 24645230
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.
Ma C; Xie J; Liu W; Wang G; Zuo S; Wang X; Wu F
Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD008302. PubMed ID: 21069705
[TBL] [Abstract][Full Text] [Related]
9. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone.
Berg G; Lindstedt G; Suurküla M; Jansson S
J Endocrinol Invest; 2002 Jan; 25(1):44-52. PubMed ID: 11883865
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer treatment in Spanish hospitals.
Vallejo JA; Muros MA
Rev Esp Med Nucl Imagen Mol; 2017; 36(6):362-370. PubMed ID: 28539216
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis.
Tu J; Wang S; Huo Z; Lin Y; Li X; Wang S
Radiother Oncol; 2014 Jan; 110(1):25-30. PubMed ID: 24485353
[TBL] [Abstract][Full Text] [Related]
13. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants.
Lassmann M; Luster M; Hänscheid H; Reiners C
J Nucl Med; 2004 Apr; 45(4):619-25. PubMed ID: 15073258
[TBL] [Abstract][Full Text] [Related]
14. Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen.
Borget I; Remy H; Chevalier J; Ricard M; Allyn M; Schlumberger M; De Pouvourville G
Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1457-63. PubMed ID: 18385999
[TBL] [Abstract][Full Text] [Related]
15. Thyroid remnant ablation in patients with papillary cancer: a comparison of low, moderate, and high activities of radioiodine.
Kusacic Kuna S; Samardzic T; Tesic V; Medvedec M; Kuna K; Bracic I; Despot M; Dodig D
Nucl Med Commun; 2009 Apr; 30(4):263-9. PubMed ID: 19247212
[TBL] [Abstract][Full Text] [Related]
16. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in
Plyku D; Hobbs RF; Huang K; Atkins F; Garcia C; Sgouros G; Van Nostrand D
J Nucl Med; 2017 Jul; 58(7):1146-1154. PubMed ID: 28104741
[TBL] [Abstract][Full Text] [Related]
17. Comparison of treatment efficacy 1 and 2 years after thyroid remnant ablation with 1110 versus 5550 MBq of iodine-131 in patients with intermediate-risk differentiated thyroid cancer.
Aghaei A; Ayati N; Shafiei S; Abbasi B; Zakavi SR
Nucl Med Commun; 2017 Nov; 38(11):927-931. PubMed ID: 28834790
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic and dosimetric effects of (131)I in patients with differentiated thyroid carcinoma: comparison between stimulation with rhTSH and thyroid hormone withdrawal treatments.
da Silva MA; Valgôde FG; Gonzalez JA; Yoriyaz H; Guimarães MI; Ribela MT; Buchpiguel CA; Bartolini P; Okazaki K
Radiat Environ Biophys; 2016 Aug; 55(3):317-28. PubMed ID: 27013085
[TBL] [Abstract][Full Text] [Related]
19. I-131 biokinetics of remnant normal thyroid tissue and residual thyroid cancer in patients with differentiated thyroid cancer: comparison between recombinant human TSH administration and thyroid hormone withdrawal.
Hong CM; Kim CY; Son SH; Jung JH; Lee CH; Jeong JH; Jeong SY; Lee SW; Lee J; Ahn BC
Ann Nucl Med; 2017 Oct; 31(8):582-589. PubMed ID: 28677070
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective.
Mernagh P; Campbell S; Dietlein M; Luster M; Mazzaferri E; Weston AR
Eur J Endocrinol; 2006 Sep; 155(3):405-14. PubMed ID: 16914594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
